Also trades as: 4875.T (JPX) · $vol 0M
MNOV NASDAQ
MediciNova, Inc.
1W: -31.0%
1M: +24.5%
3M: +23.6%
YTD: +33.8%
1Y: +42.4%
3Y: -14.8%
5Y: -54.4%
$1.78
+0.15 (+9.20%)
Weekly Expected Move ±28.0%
$1
$1
$2
$2
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (15)
At a glance: stocks gapping down premarket
Beyond GLP-1 injectables, who wins the next phase for obesity drugs?
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
MediciNova to Participate at the 38th Annual ROTH Conference
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova, Inc. (NASDAQ:MNOV) Receives $7.00 Average Target Price from Analysts
VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis
2026 New Year's Greetings from the CEO
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND